Researchers from Kumamoto University have identified a liver-derived protein, serine protease inhibitor A1 (SerpinA1), as a ...

Cirius Therapeutics, Inc. today announced Robert Beardsley, Ph.D., President & CEO, and Jerry Colca, Ph.D., CSO, will present and host a roundtable discussion, "Unlocking the Next Frontier of ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Managing blood sugar levels has become increasingly crucial for overall health and well-being in today's fast-paced world.

AquaSculpt is a natural weight loss supplement created by Dr. Blaine Schilling, a top New York City doctor specializing in ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

A new study has linked morning coffee-drinking to a reduced risk of cardiovascular disease – but our morning brew can help ...

Topline data were announced from the phase 3 THRIVE-2 study evaluating veligrotug in patients with chronic thyroid eye ...

ACELYRIN, INC. (SLRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 billion in annual sales or be clinical "game changers" in the next five ...

NDAQ:VRDN) Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease ...